Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Alder, Umia and the founders in connection with the sale of Umia Innovation to TSG
Mandate

Vinge advises Alder, Umia and the founders in connection with the sale of Umia Innovation to TSG

September 15, 2023 M&A

Vinge has advised Alder, Umia and the founders in connection with the sale of Umia Innovation to The Specialist Group (TSG), a portfolio company of Oaktree Capital Management.

Umia Innovation, with offices located in Umeå, Skellefteå och Örnsköldsvik, provides knowledge-based consultancy services within processing, technology and leadership. The company has customers within, among other things, the mining industry, forestry, medical technology, the car industry and the energy sector. Umia Innovation has changed its name to Altio in connection with the transaction.

Vinge’s team primarily consisted of Johan Larsson, Karl Klackenberg, Ellinor Wargenbrant, Carl Fredrik Wachtmeister, Robin Fagerström (M&A), as well as Jessica Henning and Emy Rydén (project assistants).

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026